There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Anavex Life Sciences (AVXL – Research Report) and OncoCyte (OCX – Research Report) with bullish sentiments.
Anavex Life Sciences (AVXL)
BTIG analyst Yun Zhong reiterated a Buy rating on Anavex Life Sciences yesterday and set a price target of $35.00. The company’s shares closed last Wednesday at $7.31, close to its 52-week low of $7.23.
According to TipRanks.com, Zhong is ranked 0 out of 5 stars with an average return of
Anavex Life Sciences has an analyst consensus of Strong Buy, with a price target consensus of $39.00, implying a 407.2% upside from current levels. In a report released yesterday, JonesTrading also reiterated a Buy rating on the stock with a $40.00 price target.
See the top stocks recommended by analysts >>
OncoCyte (OCX)
In a report released yesterday, Mark Massaro from BTIG reiterated a Buy rating on OncoCyte, with a price target of $4.00. The company’s shares closed last Wednesday at $1.13, close to its 52-week low of $1.09.
According to TipRanks.com, Massaro is a 3-star analyst with an average return of
OncoCyte has an analyst consensus of Strong Buy, with a price target consensus of $3.95.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AVXL:
- Analysts Offer Insights on Consumer Goods Companies: Performance Food Group (PFGC) and Boxed (BOXD)
- Recursion Pharmaceuticals (RXRX) Gets a Hold Rating from SVB Securities
- SVB Securities Thinks Reneo Pharmaceuticals’ Stock is Going to Recover
- Diversey Holdings (DSEY) Gets a Hold Rating from Mizuho Securities
- Pardes Biosciences (PRDS) Initiated with a Buy at SVB Securities
